



PTO/SB/08 Equivalent

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application No.	10/601070
Filing Date	June 20, 2003
First Named Inventor	Andersson, C.
Art Unit	1625
Examiner	Charanjit Aulakh
Attorney Docket No.	ACADIA.020A

(Multiple sheets used when necessary)

SHEET 1 OF 1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
CA	1	2004/0006081 A1	01/08/2004	Burrows, et al.	_____
CA	2	5,216,165	06/01/1993	Mobilio, et al.	_____

2405740
022806

Examiner Signature	AULAKH	Date Considered	6/20/06
--------------------	--------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 6

Application No.	10/601070
Filing Date	June 20, 2003
First Named Inventor	Andersson, et al.
Art Unit	1625
Examiner	Charanjit Aulakh
Attorney Docket No.	ACADIA.020A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
CA	1	3,983,234	09-28-1976	Sayers	
CA	2	4,138,492	02-06-1979	Noverola, et al.	
CA	3	4,255,432	03-10-1981	Kluge, et al.	
CA	4	4,353,900	10-12-1982	Clark	
CA	5	4,367,232	01-04-1983	Boix-Iglesias, et al.	
CA	6	5,025,013	06-18-1991	Barreau et al.	
CA	7	5,461,066	10-24-1995	Gericke	
CA	8	5,795,894	08-18-1998	Shue, et al.	
CA	9	5,869,488	02-09-1999	Shue, et al.	
CA	10	5,877,173	03-02-1999	Olney, et al.	
CA	11	5,912,132	06-15-1999	Brann	
CA	12	5,955,281	09-21-1999	Brann	
CA	13	6,107,324	08-22-2000	Behan, et al.	
CA	14	6,140,509	10-31-2000	Behan, et al.	
CA	15	6,150,393	11-21-2000	Behan, et al.	
CA	16	6,911,452	06-28-2005	Schlienger, N.	
CA	17	2002/0004513 A1	01-10-2002	Andersson, et al.	
CA	18	2004/0006081	01/08/2004	Burrows, et al.	
CA	19	2002-0165225 A1	11-07-2002	Hamied, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
CA	20	CA 984843	03/02/1976	Wyeth, et al.		
CA	21	EP 0061333	09-29-1982	Syntex		
CA	22	EP 0379441	07-25-1990	Rhone-Poulenc Sante		
CA	23	EP 0005318	11-14-1979	Janssen Pharm.		
CA	24	EP 0548015	06-23-1993	Borzetta, et al.		
CA	25	EP 0625507	11-23-1994	Nishin Flour Milling		

Examiner Signature

AULAKH

Date Considered

6/29/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
SHEET 2 OF 6	Examiner	Charanjit Aulakh
	Attorney Docket No.	ACADIA.020A

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
CA	26	WO 94/27967	12-18-1994	Smithkline		
CA	27	HU 157325	03-19-1998	Rudolf, et al.		
CA	28	WO 97/11940	04-03-1997	Fisher, et al.		
CA	29	WO 97/38665	10-23-1997	Merck & Co.,		
CA	30	WO 97/38984	10-23-1997	Dupont Merck Pharma.		
CA	31	WO 98/17646	10-15-1997	Pieper		
CA	32	WO 97/08166	03-06-1997	Schering Corp.		
CA	33	WO 98/50534	11-12-1998	Smithkline Beecham		
CA	34	WO 98/11128	03-19-1998	Rudolf, et al.		
CA	35	WO 99/52927	10-21-1999	Behan		
CA	36	WO 00/69810	11-23-2000	Ling, et al.		
CA	37	WO 00/23076	04-27-2000	Suntory Limited		
CA	38	WO 00/59497	10-12-2000	Merck & Co.,		
CA	39	WO 01/44191	06-21-2001	Thurieu, et al.		
CA	40	WO 00/56335	09-28-2000	Ellman, et al.		
CA	41	WO 02/079186	10-10-2002	Hoffman, et al.		
CA	42	WO 01/87839	09/13/2001	Astrazeneca AB		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
CA	43	Adam, et al. <i>Psychopharmacology</i> . (1989) 99 (2) 219-221	bA
CA	44	Bakshi, et al., <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 271 No. 2 (1994) pp 787-794.	
CA	45	Barr, et al. <i>The Journal of biological Chemistry</i> , Vol. 272 No. 52, (1997) pp. 32979-32987.	
CA	46	Bassus, et al. <i>Bur. J. Med. Chem, Chimica Therapeutica</i> , July-August 1974 pp 416-423	
CA	47	Bennett, et al. <i>Neurology</i> 43, August 1993 pp. 1551-1555.	

Examiner Signature	<i>AULAKH</i>	Date Considered	<i>6/20/06</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 3 OF 6	Attorney Docket No.	ACADIA.020A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
CA	48	Bhatia, et al. <i>J. Med Chem.</i> , 1996, 39, pp. 3938-3950	
CA	49	Bibbiani, et al. <i>Neurology</i> 57, 2001 pp. 1829-1834.	
CA	50	Blakley et al. <i>The Journal of Pharmacology and Experimental Therapeutics</i> (2001) 299(1) 277-289	
CA	51	Blier et al. <i>J. of Psychiatry & Neuroscience</i> (2001) 26(1) 37-43	
CA	52	Boullin, D. J. (Ed.). <i>Serotonin in Mental Abnormalities, Biochemical Indicators of Central Serotonin Function</i> , 1978, John Wiley: New York.	
CA	53	Birkmayer, et al, <i>Journal of Neural Transmission</i> 35, pp. 93-116 (1974)	
CA	54	Butcher, et al. <i>Letters to the Editor, J. Pharm Pharmac</i> (1970) 22, pp. 313-316	
CA	55	Caroon, et al. <i>J. Med. Chem.</i> (1981) 24, 1320-1326	
CA	56	Clark, et al. <i>J. Med. Chem.</i> Vol. 26, pp. 855-861 (1983)	
CA	57	DeClerck, et al. <i>Current Therapeutic Research</i> , (1987) 41 4 427:432	
CA	58	Delecluse, et al. <i>Movement Disorders</i> , Vol. 13, No. 5 1998 pp. 846-847	
CA	59	Durif, et al. <i>Neurology</i> 48 1997 pp. 658-662	
CA	60	Eichelbaum, et al. <i>Clinical and Experimental Pharmacology and Physiology</i> (1996) 23 pp. 983-985.	
CA	61	Ermakov et. al. Use of Mass spectrometry in Structural and stereochemical studies (1981)	
CA	62	Everett, et al. <i>Science</i> Vol. 168 May 1970 pp. 849-850	
CA	63	Factor, et al. <i>Movement Disorders</i> Vol 7 No. 2 1992 pp. 125-131	
CA	64	Factor, et al. <i>Movement Disorders</i> Vol 16 No. 1 2001 pp. 135-139.	
CA	65	Fisera, et al. <i>Monatshefte Fur Chemie</i> 125 (1994) pp. 909-919	
CA	66	Friedman, <i>Movement Disorders</i> Vol 9 No. 3 1994 pp. 321-324.	

Examiner Signature	<i>AULAKH</i>	Date Considered	6/20/06
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 4 OF 6	Attorney Docket No.	ACADIA.020A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
CA	67	Freidman, et al. <i>Movement Disorders</i> Vol 15 No. 2 2000 pp. 201-211	
CA	68	Fuller, <i>Biology of Serotonin Transmission</i> , 1982, Chapter 9, pp. 221-247.	
CA	69	Gainetdivnov, et al. <i>Trends in Neuroscience</i> (2001) 24(9) 527-533	
CA	70	Gamma, <i>Neuropsychopharmacology</i> 2000, Vol. 23, No. 4, pp. 388-395	
CA	71	Gawley, R. E. and Jeffrey Aube (Eds.). <i>Principles of Asymmetric Synthesis</i> , 1996, Elsevier Science Ltd.: New York	
CA	72	Gershon, et al. <i>The Peripheral Actions of 5-Hydroxyptamine</i> , 1989, Chapter 11, pp. 246-273	
CA	73	Gstach, et al. <i>Papers</i> , September 1990 pp. 803-808.	
CA	74	Harper, et al. <i>J. Medicinal Chemistry</i> , April 1964. vol. 7, pp. 729-732.	
CA	75	Herrick-Davis, et al. <i>The Journal of Pharmaocology and Experimental Therapeutics</i> , 2000, vol. 295 No. 1 pp. 226-232.	
CA	76	Idzikowski, et al. <i>Br J. Clin. Pharmacol</i> , (1991) 31 (2) : 193-6.	
CA	77	Julius, et al. <i>Neurobiology</i> , Vol. 87, pp. 928-932 1990	
CA	78	Landolt HP, et al. <i>Neuropsychopharmacolgy</i> (1999) 21 (3) 455-466	
CA	79	Leysen, et al. <i>Nature</i> , Vol 272, 9 March 1978, pp. 171.	
CA	80	Liechti, et . al. <i>Neuropsychopharmacology</i> 2001, Vol. 24, No. 3, pp. 240-252.	
CA	81	Linder, et al. <i>Clinical Chemistry</i> , vol 43, 2, pp 1997 pp. 254-266	
CA	82	Mansbach, et al. <i>Psychopharmacology</i> , (1988) 94, pp. 507-514.	
CA	83	Mavunkel, et al. <i>J. Med. Chem</i> (1996), vol 39, pp. 3169-3173.	
CA	84	Mayer, et al. <i>Pharmacopsychiatry</i> (2003) 36: 150-155	
CA	85	Metzler, et al. <i>Neuropsychopharmacology</i> (1995) 12, 39-45	

Examiner Signature	<i>AULAKH</i>	Date Considered	<i>6/20/06</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
	Examiner	Charanjit Aulakh
SHEET 5 OF 6	Attorney Docket No.	ACADIA.020A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
CA	86	Meng, et al. <i>Tetrahedron</i> , vol 47, No. 32 pp. 6251-6251, (1991)	
CA	87	Miyata et al. <i>J. of Cardiovascular Pharmacology</i> (2000) 35(2) 294-301	
CA	88	Mullen, et al. <i>J. Med. Chem</i> (2000), vol 43, pp. 4045-4050.	
CA	89	Ng, et al. <i>Science</i> , Vol. 170, (1970) pp. 76-77	
CA	90	Nordstrom, et al. <i>Psychopharmacology</i> , (1993) vol. 110, pp. 365-367	
CA	91	Pace, et al. <i>Proc. Natl. Acad. Sci</i> , Vol 88, (1991) pp. 7031-7035.	
CA	92	Paiva, et al. <i>Psychopharmacology (Berl)</i> 1988, 96 (3) 395-9	
CA	93	Sadzot, et al. <i>Psychopharmacology</i> , (1989) vol. 98 pp. 495-499.	
CA	94	Sharpley, et al. <i>Neuropharmacology</i> (1994), 33, (3-4), 467-71.	
CA	95	Schins et al. <i>Psychosomatic Medicine</i> (2003) 65:729-737	
CA	96	Smith, et al. <i>J. Med. Chem.</i> (1995), vol 38, pp. 3772-3779.	
CA	97	The Parkinson Study Group. 1999. <i>Low-Dose Clozapine for the Treatment for Drug-Induced Psychosis in Parkinson's Disease</i> , vol. 340(10):757-763.	
CA	98	The French Study Group. 1999. <i>Clozapine in Drug-Induced Psychosis in Parkinson's Disease</i> , The Lancet, 353:2041-2042.	
CA	99	Tsukamoto, et al. <i>Chem. Pharm Bull.</i> 43 (1995) pp. 1523-1529.	
CA	100	Vallar, et al. <i>Nature</i> , Vol 330, December 1987, pp. 566-568.	
CA	101	Van Laar, et al. <i>Psychopharmacology</i> (2001), 154(2) 189-97	
CA	102	Viola, et al. <i>Clin Neurophysio</i> 2002 113(3): 429-34	
CA	103	Wade, et al. <i>J. Comb. Chem.</i> 2000 2, pp. 266-275	
CA	104	Yoshida, et al. <i>Clinical Neuropharmacology</i> , Vol. 21, No. 1 pp 68-69.	

Examiner Signature	<i>AULAKH</i>	Date Considered	<i>6/20/06</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 6 OF 6	Attorney Docket No.	ACADIA.020A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
CA	105	Chemical Abstracts, (25305) vol. 73, 1970, p. 350	

2599818
051506

Examiner Signature	AULAKH	Date Considered	8/20/08
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T¹ - Place a check mark in this area when an English language Translation is attached.